TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04576026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mental fatiguing task
Description: a 30-minute computerized Stroop test will be used to induce mental fatigue before exercise intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mental fatiguing task
Description: a 30-minute computerized Stroop test will be used to induce mental fatigue before exercise intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 45 - minute simulated soccer game
Description: an intermittent running protocol using intensities and speeds seen in soccer will be used to simulate the physiological demands of the sport

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 45 - minute simulated soccer game
Description: an intermittent running protocol using intensities and speeds seen in soccer will be used to simulate the physiological demands of the sport

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive function
Description: The Stroop test and a complex reaction time test will be used to assess cognitive function during exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive function
Description: The Stroop test and a complex reaction time test will be used to assess cognitive function during exercise.
Study: NCT01311609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane
Description: Systane Lubricant Eye Drops \[1-2 Drops in each eye four times daily (QID)\]
Study: NCT01561521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKF-1
Description: 1 drop AKF-1 0.025% in each eye at 2 separate times during a 14 day period
Study: NCT01709071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose Sabin-IPV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose adjuvanted Sabin-IPV
Study: NCT06074107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEBT-908 for injection
Description: The initial dose is 22.5mg/m2, intravenous drip, on the 1st, 3rd, 5th, 8th, 10th and 12th day of each cycle，21 days as a cycle, 6 cycles as the total treatment cycle.
Study: NCT02639481

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard physiotherapy
Description: Classical standard physiotherapy, including measures to verticalize patients by means of orthesis, classical tilt tables, or castings
Study: NCT03420729

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastroscopy
Description: a thin, flexible tube called an end oscope is used to look inside the oesophagus (gullet), stomach and first part of the small intestine (duodenum)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastroscopy
Description: a thin, flexible tube called an end oscope is used to look inside the oesophagus (gullet), stomach and first part of the small intestine (duodenum)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: magnetic assisted capsule endoscopy
Description: The patient will be given 500 to 1000mls of water with 6 drops of simethicone added to drink. This is to enable adequate distension of the stomach. The patient then swallows the capsule in the presence of the PI. MACE of the oesophagus and stomach will be carried out by the PI. Once the PI is satisfied that an adequate examination has been completed the capsule will be allowed to pass into and through the small bowel.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetic assisted capsule endoscopy
Description: The patient will be given 500 to 1000mls of water with 6 drops of simethicone added to drink. This is to enable adequate distension of the stomach. The patient then swallows the capsule in the presence of the PI. MACE of the oesophagus and stomach will be carried out by the PI. Once the PI is satisfied that an adequate examination has been completed the capsule will be allowed to pass into and through the small bowel.
Study: NCT04523909

Intervention type: DIAGNOSTIC_TEST
Intervention: Trajectory of neuroinflammatory proteins in CSF and blood
Description: Kinetics of neuroinflammatory markers in CSF and blood
Study: NCT00079235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03843333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Ji Quan: Moving for Better Balance
Description: TJQMBB is an evidence-based, Centers for Disease Control and Prevention (CDC)-recommended, group falls prevention program based in Tai Chi that has been shown to reduce falls risk, improve physical function, and improve cognition. The program is delivered in 1-hour sessions twice weekly over 24 weeks, with the first 12 weeks spent learning the basic Tai Ji Quan forms and the second 12 weeks focused on variations in practice that progressively increase physical and cognitive demands. A physical therapist at Dartmouth is an authorized TJQMBB trainer and will train the CHWs to deliver the intervention and provide remote supervision monthly.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: BA is a brief intervention for depressive symptoms that focuses on engagement in positively-reinforcing activities and decreasing activity avoidance. CHWs will be trained by Dartmouth psychologists to deliver a brief behavioral activation program to encourage participants to increase their involvement in meaningful activities. BA will be delivered in one-hour sessions in the home every other week for 12 weeks. Supervision will be provided remotely on a weekly basis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resource Navigation
Description: CHWs will assess participants' unmet psychosocial needs and assist them in identifying and connecting them with resources to address these needs.Types of assistance may include identifying transportation services, assisting with applications for benefits, linking participants to Meals on Wheels and other local food resources, and connecting participants to community programs for older adults. We expect that participant needs and services delivered will vary and acknowledge that this intervention component will not be standardized due to the nature of this work.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Comparison participants will receive a detailed resource guide on community supports for older adults. The research team will facilitate referrals to local resources (e.g. the Dartmouth Aging Resource Center) if desired by participants. Data from research assessments of cognition, depressive symptoms, mobility, and functional status will be provided to the primary care team for follow-up and intervention as needed.
Study: NCT02714998

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: single dose systemic methotrexate administration (50 mg/m2)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: single dose systemic methotrexate administration (50 mg/m2)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: salpingectomy
Description: Laparoscopic unilateral salpingectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: salpingectomy
Description: Laparoscopic unilateral salpingectomy
Study: NCT05819177

Intervention type: OTHER
Intervention: Rehabilitation program
Description: This group of patients underwent standard rehabilitation programs set by national guidelines.
Study: NCT02147652

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized music
Study: NCT01628263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow up Clinic for High risk participants
Description: Families where either or both parents are screened to be at risk of PTSD or depression are randomised in a 1:1 ratio to the intervention or control arm. Those in the intervention arm will receive an offer of a follow up clinic two months post discharge, staffed by the unit Clinical Psychologist, a PICU doctor and PICU nurse. Those in the control arm will not be offered a follow up clinic.
Study: NCT00582855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQW051

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01835847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipepidine Hibenzate
Study: NCT01123356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: * Ofatumumab 2000 mg (300 mg on first cycle) IV on day 1 for up to 6 cycles (28 day cycles)~* Treatment to be administered for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: -Lenalidomide 10 mg (5 mg on first cycle) PO days 8-28 for up to 6 cycles (28 day cycles)
Study: NCT02639481

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erigo®Pro group without FES
Description: Use of the Erigo®Pro device to verticalize patients to above 60° while performing robotic stepping leg movements. FES ist not used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erigo®Pro group with FES
Description: Use of the Erigo®Pro device to verticalize patients to above 60° while performing robotic stepping leg movements. FES is applied during then whole treatment session, providing electrical stimulation to the muscles of the upper and lower leg, synchronous to the robotic stepping movements
Study: NCT01143090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone HCl
Description: 40 mg Lurasidone tablets, 40 - 120 mg per day for up to 6 months
Study: NCT02183961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restech

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peptest

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Detection of pepsin in adenoid specimen
Study: NCT03406299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur
Description: Tegafur(S-1) 35 mg/m2/b.i.d., day 1 - 7 (maximum dose: 120 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin 30 mg/b.i.d., day 1-7
Study: NCT02697162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Antiseptic-coated catheter
Description: Antiseptic-coated hydrophilic intermittent urinary catheter with octenidine chloride

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Hydrophilic catheter
Description: Hydrophilic intermittent urinary catheter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octenidine chloride
Description: Antiseptic
Study: NCT02023151

Intervention type: DRUG
Group type: OTHER
Intervention: Omalizumab
Study: NCT03406299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m2 in 250 mL of 5% Glucose, given as 2-hour intra- venous infusion, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 800 mg/m2 in 250 mL of normal saline, given as fixed dose-rate (, 10 mg/m2/min) infusion, day 1; After the administration of gemcitabine, the infusion line should be flushed with 20 ml of normal saline and then 50 ml of 5% glucose solution before the administration of oxaliplatin. in SLOG arm.~Gemcitabine 1000 mg/m2 in 100 mL of normal saline, IV drip for 30 mins on D1 and D8 ，in GC arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 25 mg/m2 in 250ml of normal saline, IV drip for 2 hours on D1 and D8
Study: NCT01839032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine cisplatin radiotherapy
Description: During the induction period, patients received chemotherapy for two 3-week cycles. Bolus intravenous vinorelbine 25 mg/m², was administered on day 1, then cisplatin 80 mg/m² was administered over 1-hour infusion. Vinorelbine 60 mg/m² was also administered on day 8.~Patients with objective response (OR) or no change (NC) continued the concomitant period (CP) including two additional 3-week cycles of radio chemotherapy (vinorelvine 20 mg D1 D3 D5 Cisplatin 80 mg/m² 66 Gy).
Study: NCT02670161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
Description: brain tumors (lamotrigine, levetiracetam, valproic acid), epilepsy (lamotrigine, levetiracetam, valproic acid), mild cognitive impairment (donepezil, rivastigmine, memantine), migraine (amitriptyline, propranolol, topiramate), migraine (sumatriptan, rizatriptan, zolmitriptan), mild traumatic brain injury (omega-3 fatty acids, education only), multiple sclerosis (ACTH, methylprednisolone), neuropathy (duloxetine, pregabalin, amitryptiline), Parkinson's disease (pramipexole, ropinerole, rotigotine), restless legs syndrome (pramipexole, ropinerole, rotigotine), stroke (aspirin, clopidogrel).
Study: NCT01561521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKF-1
Description: 1 drop AKF-1 0.035% in each eye at 2 separate times during a 14 day period
Study: NCT02670161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
Description: brain tumors (lamotrigine, levetiracetam, valproic acid), epilepsy (lamotrigine, levetiracetam, valproic acid), mild cognitive impairment (donepezil, rivastigmine, memantine), migraine (amitriptyline, propranolol, topiramate), migraine (sumatriptan, rizatriptan, zolmitriptan), mild traumatic brain injury (omega-3 fatty acids, education only), multiple sclerosis (ACTH, methylprednisolone), neuropathy (duloxetine, pregabalin, amitryptiline), Parkinson's disease (pramipexole, ropinerole, rotigotine), restless legs syndrome (pramipexole, ropinerole, rotigotine), stroke (aspirin, clopidogrel).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
Description: brain tumors (lamotrigine, levetiracetam, valproic acid), epilepsy (lamotrigine, levetiracetam, valproic acid), mild cognitive impairment (donepezil, rivastigmine, memantine), migraine (amitriptyline, propranolol, topiramate), migraine (sumatriptan, rizatriptan, zolmitriptan), mild traumatic brain injury (omega-3 fatty acids, education only), multiple sclerosis (ACTH, methylprednisolone), neuropathy (duloxetine, pregabalin, amitryptiline), Parkinson's disease (pramipexole, ropinerole, rotigotine), restless legs syndrome (pramipexole, ropinerole, rotigotine), stroke (aspirin, clopidogrel).
Study: NCT02802332

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Footlength Card
Description: The footlength card has an image of a baby's foot. The card is to be held up against the baby's foot after birth; if a baby's foot is smaller than the image, or if the woman/family member is concerned about the health of their baby, they can call the number printed on the card and hear a pre-recorded message about basic care for newborn babies
Study: NCT00142532

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture and Questionnaires
Description: Acupuncture 30 day treatment BL12 - 19 and extra point Wei Guan Xia Shu Each side of the spine,1.5 cun (\~2.5cm) lateral to the lower border of spinous process of the T2 - 10 spinal vertebrae respectively 4 weeks ST36, Below the knee, 3 cun (\~7.5cm) inferior to the lower border of the patella, one finger breadth lateral to the anterior crest of the tibia. One week following removal of epidural.~Shenmen, bilaterally. At the lateral 1/3 of the triangular fossa in the auricle.One week following removal of epidural.~Questionnaires 30 / 60 / 90 Day and 12 Month Follow-up-Numerical rating scale of pain; total opioid use; Medication Quantification Scale; length of stay; Brief Pain Inventory

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Acupuncture, Questionnaires
Description: The back studs will be placed halfway between the upper and lower border of spinous processes T2 to T10, approximately 0.5 cun (\~1.25cm) from the spine. The leg studs will be placed at 2 cun (\~5cm) posterior to GB34 on the posterior of the lower leg. No studs will be placed in the ear; rather studs will be placed on the anterior arm, 3 cun (\~ 5cm) proximal and 3 cun (\~ 5cm) medial to the midpoint of the antecubital crease.~Pain will be assessed by a 0 - 10 point numerical rating scale (NRS) marked no pain at one end and worst pain at the other.
Study: NCT01864980

Intervention type: PROCEDURE
Intervention: blood transfusion, intermittent Hbsatlab measurement
Description: In the Hbsatlab group, RBC administration and its timing will be based on intermittent Hbsatlab measurement (routine care)

Intervention type: PROCEDURE
Intervention: blood transfusion, based on continuous SpHb readings
Description: RBC administration and its timing will be based on continuous SpHb readings while Hbsatlab values, measured every 30 min. by an objective observer, will not be visible to the attending anaesthetist.
Study: NCT02181881

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DuoPACT
Description: Intervention sessions are administered weekly by a counselor.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life Steps
Description: Intervention sessions are administered weekly by a counselor.
Study: NCT03855384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU)
Description: TQB2450 1200mg IV ，cisplatin 75 mg/m\^2 IV or carboplatin AUC 5 IV on Day 1 of each week in 3-week cycles (6 cycle maximum); plus 5-FU 750 mg/m\^2/day IV continuous from Day 1-5 of each 3- week cycle (6 cycle maximum).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU)
Description: placebo 1200mg IV ，cisplatin 75 mg/m\^2 IV or carboplatin AUC 5 IV on Day 1 of each week in 3-week cycles (6 cycle maximum); plus 5-FU 750 mg/m\^2/day IV continuous from Day 1-5 of each 3- week cycle (6 cycle maximum).
Study: NCT03077503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 1 µg/kg diluted to 20 ml with 0.9% normal saline was administration. If adverse events were occurred, the patient will receive rescue drugs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 1 µg/kg diluted to 2 ml with 0.9% normal saline was administration. If adverse events were occurred, the patient will receive rescue drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% normal saline
Description: 0.9% normal saline was use to dilute the study drugs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% normal saline
Description: 0.9% normal saline was use to dilute the study drugs

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skull pins
Description: Skull pins were use to stabilized the patent' s head during surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Skull pins
Description: Skull pins were use to stabilized the patent' s head during surgery
Study: NCT00534235

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decompression
Description: Either microsurgical decompression or laminotomy to remove bone impinging on nerves causes the patient pain

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decompression
Description: Either microsurgical decompression or laminotomy to remove bone impinging on nerves causes the patient pain

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Posterolateral Fusion and Implantation of Pedicle Screws

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of coflex Interlaminar Technology
Study: NCT00610493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg By Vein Over 90 Minutes on Day 1 of Each 21 Day Cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: 5 mg By Vein Over 30-60 Minutes on Days 1, 8, 15 of Each 21 Day Cycle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Additional Blood Drawn
Description: 2 teaspoons each time: 4xDay Cycle 1 after start of first infusion; at Day 8 of Cycle 1; at Day 15 of Cycle 1; and at end of Cycle 1.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: First tumor biopsy during screening visit and Second at the end of Cycle 1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DCE-MRI Scan
Description: DCE-MRI (dynamic contrast-enhanced magnetic resonance imaging) scan during screening visit, at 24-48 hours after the start of Cycle 1, and at the end of Cycle 1
Study: NCT00786695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: esomeprazole (40 mg o d) for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical looking Placebo, same regimen, for 14 days
Study: NCT04708717

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation Rate
Description: Psychophysical training listening to stimulation rate as a cue for auditory pitch perception. The intervention is the listening rehabilitative exercises. Exercises are completed daily as 30-minute sessions for 2 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stimulation Rate
Description: Psychophysical training listening to stimulation rate as a cue for auditory pitch perception. The intervention is the listening rehabilitative exercises. Exercises are completed daily as 30-minute sessions for 2 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Electrode Location
Description: Psychophysical training listening to electrode location as a cue for auditory pitch perception. The intervention is the listening rehabilitative exercises. Exercises are completed daily as 30-minute sessions for 2 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electrode Location
Description: Psychophysical training listening to electrode location as a cue for auditory pitch perception. The intervention is the listening rehabilitative exercises. Exercises are completed daily as 30-minute sessions for 2 weeks.
Study: NCT02196285

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double viral (MR) vaccine
Description: Measles and Rubella vaccine, as single arm
Study: NCT01451775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: high dose of empagliflozin after overnight fasting for at least 10 h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: low dose empagliflozin after overnight fasting for at least 10 h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: high dose of empagliflozin after a standardised high fat breakfast
Study: NCT01561521

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AKF-1
Description: 1 drop 0% in each eye at 2 separate times during a 14 day period